STAT: Biosimilars, The Cure for Sky-High Drug Prices or a Stake in the Heart of Innovation?
Back Bay Life Science Advisors Senior Vice President, Michelle Hoffmann, wrote a piece for STAT’s “first opinion” section on the U.S. biosimilar market. Titled, “Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?” the piece explains the history of U.S. biosimilars and details what the future may hold.